CY1122429T1 - Αμορφη υδροχλωρικη λερκανιδιπινη - Google Patents

Αμορφη υδροχλωρικη λερκανιδιπινη

Info

Publication number
CY1122429T1
CY1122429T1 CY20191101332T CY191101332T CY1122429T1 CY 1122429 T1 CY1122429 T1 CY 1122429T1 CY 20191101332 T CY20191101332 T CY 20191101332T CY 191101332 T CY191101332 T CY 191101332T CY 1122429 T1 CY1122429 T1 CY 1122429T1
Authority
CY
Cyprus
Prior art keywords
amorphous lercanidipine
pure
lercanidipine hydrochloride
substantially pure
hydrochloride
Prior art date
Application number
CY20191101332T
Other languages
English (en)
Inventor
Amedeo Leonardi
Gianni Motta
Fabio Berlati
Original Assignee
Recordati Ireland Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36585434&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1122429(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Recordati Ireland Limited filed Critical Recordati Ireland Limited
Publication of CY1122429T1 publication Critical patent/CY1122429T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B63/00—Purification; Separation; Stabilisation; Use of additives
    • C07B63/04—Use of additives

Abstract

Η εφεύρεση παρέχει μια ουσιαστικά καθαρή άμορφη λερκανιδιπίνη υδροχλωρική, η οποία έχει καθαρότητα τουλάχιστον 95 % καθαρή, κατά προτίμηση τουλάχιστον περίπου 97% καθαρή, περισσότερο κατά προτίμηση τουλάχιστον περίπου 99% καθαρή και ακόμη περισσότερο κατά προτίμηση τουλάχιστον περίπου 99,5 % καθαρή. Η εφεύρεση περαιτέρω παρέχει μεθόδους παρασκευής ουσιαστικά καθαρής άμορφης λερκανιδιπίνης, και φαρμακευτικές συνθέσεις, οι οποίες περιέχουν την ουσιαστικά καθαρή άμορφη λερκανιδιπίνη.
CY20191101332T 2005-02-25 2019-12-18 Αμορφη υδροχλωρικη λερκανιδιπινη CY1122429T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65683605P 2005-02-25 2005-02-25
PCT/EP2006/001782 WO2006089787A1 (en) 2005-02-25 2006-02-24 Amorphous lercanidipine hydrochloride

Publications (1)

Publication Number Publication Date
CY1122429T1 true CY1122429T1 (el) 2021-01-27

Family

ID=36585434

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20191101332T CY1122429T1 (el) 2005-02-25 2019-12-18 Αμορφη υδροχλωρικη λερκανιδιπινη

Country Status (32)

Country Link
US (1) US7820701B2 (el)
EP (1) EP1856051B1 (el)
JP (1) JP2008531515A (el)
KR (1) KR20070105979A (el)
CN (1) CN101124204A (el)
AR (1) AR052918A1 (el)
AU (1) AU2006218026B9 (el)
BR (1) BRPI0608138A2 (el)
CA (1) CA2598016A1 (el)
CY (1) CY1122429T1 (el)
DK (1) DK1856051T3 (el)
EA (1) EA014383B1 (el)
ES (1) ES2339213T3 (el)
HR (1) HRP20192302T1 (el)
HU (1) HUE046910T2 (el)
IL (1) IL184349A0 (el)
LT (1) LT1856051T (el)
ME (1) ME03659B (el)
MX (1) MX2007010093A (el)
MY (1) MY142129A (el)
NO (1) NO344559B1 (el)
NZ (1) NZ556667A (el)
PE (1) PE20061014A1 (el)
PL (1) PL1856051T3 (el)
PT (1) PT1856051T (el)
RS (1) RS59654B1 (el)
SI (1) SI1856051T1 (el)
TW (1) TW200640861A (el)
UA (1) UA90130C2 (el)
UY (1) UY29401A1 (el)
WO (1) WO2006089787A1 (el)
ZA (1) ZA200708127B (el)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4709545B2 (ja) * 2002-07-26 2011-06-22 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 修飾された低分子干渉ｒｎａ分子および使用方法
AR052918A1 (es) 2005-02-25 2007-04-11 Recordati Ireland Ltd Clorhidrato de lercanidipina amorfo
US8097729B2 (en) 2005-09-16 2012-01-17 Glenmark Generics Ltd. Polymorphic form of lercanidipine hydrochloride and process for the preparation thereof
SI2046745T1 (sl) * 2006-08-04 2014-02-28 Recordati Ireland Limited Postopek za pripravo amorfnega lerkanidipin hidroklorida
EP2101771A2 (en) * 2006-12-06 2009-09-23 Torrent Pharmaceuticals Ltd Stable lercanidipine formulation
EP2121575A2 (en) * 2007-03-05 2009-11-25 Actavis Group PTC EHF Lercanidipine hydrochloride polymorphs and an improved process for preparation of 1,1,n-trimethyl-n-(3,3-diphenylpropyl)-2-aminoethyl acetoacetate
CA2761255C (en) * 2009-05-12 2017-05-09 Corcept Therapeutics, Inc. Solid forms and process for preparing (r)-4a-ethoxymethyl-1-(4-fluoro-phenyl)-6-(4-trifluoromethyl-benzenesulfonyl)-4,4a,5,6,7,8-hexahydro-1h,1,2,6-triaza-cyclopenta[b]naphthalene
DE102010005124A1 (de) * 2010-01-19 2012-03-01 Stada Arzneimittel Ag Feste pharmazeutische Zusammensetzung umfassend Lercanidipin
EP2444394A1 (en) 2010-10-21 2012-04-25 Alembic Pharmaceuticals Limited Process for the preparation of amorphous form of lercanidipine HCI
CN102531999B (zh) * 2011-12-16 2014-02-26 华润赛科药业有限责任公司 无定形盐酸乐卡地平及其制备方法
CN102558032B (zh) * 2011-12-16 2014-02-26 华润赛科药业有限责任公司 一种无定形盐酸乐卡地平及其制备方法
CN102600146B (zh) * 2012-04-11 2014-10-08 兆科药业（合肥）有限公司 一种盐酸乐卡地平和氯沙坦钾复方制剂及其制备方法
WO2015029066A1 (en) * 2013-08-29 2015-03-05 Cadila Healthcare Limited Polymorphic form of pyrrole derivative and intermediate thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8403866D0 (en) * 1984-02-14 1984-03-21 Recordati Chem Pharm Diphenylalkylaminoalkyl esters
US5696139A (en) * 1995-05-12 1997-12-09 Recordati S.A., Chemical And Pharmaceutical Company Use of S-enantiomers of 1,4-dihydropyridine derivatives for treating heart failure
US5912351A (en) * 1995-05-12 1999-06-15 Recordati, S.A. Chemical And Pharmaceutical Company Anhydrous 1,4-Dihydropyridines and salts thereof
IT1274480B (it) 1995-05-12 1997-07-17 Recordati Chem Pharm Procedimento migliorato per la preparazione della lercanidipina cloridrato
US20030069285A1 (en) * 2001-08-06 2003-04-10 Recordati Ireland Limited Novel solvate and crystalline forms of lercanidipine hydrochloride
ITMI20011726A1 (it) 2001-08-06 2003-02-06 Recordati Ind Chimica E Farma Forme polimorfe della lercanidipina cloridrato
ITMI20011727A1 (it) 2001-08-06 2003-02-06 Recordati Ind Chimica E Farma Solvati della lercanidipina cloridrato e nuove forme cristalline della lercanidipina cloridrato ottenute da essi
US6852737B2 (en) * 2001-08-06 2005-02-08 Recordati Ireland Limited Crude and crystalline forms of lercanidipine hydrochloride
US20030180355A1 (en) * 2001-10-16 2003-09-25 Amedeo Leonardi Combination therapy for hypertension
US20040147566A1 (en) * 2002-10-16 2004-07-29 Amedeo Leonardi Lisinopril/lercanidipine combination therapy
JP4749660B2 (ja) * 2002-10-16 2011-08-17 武田薬品工業株式会社 安定な固形製剤
US20040198789A1 (en) * 2003-02-28 2004-10-07 Recordati Ireland Limited Lercanidipine/ARB/diuretic therapeutic combinations
TW200613275A (en) * 2004-08-24 2006-05-01 Recordati Ireland Ltd Lercanidipine salts
TW200616681A (en) 2004-10-05 2006-06-01 Recordati Ireland Ltd Lercanidipine capsules
KR100651212B1 (ko) 2004-10-27 2006-12-01 제일약품주식회사 무정형 레르카니디핀의 제조방법
AR052918A1 (es) 2005-02-25 2007-04-11 Recordati Ireland Ltd Clorhidrato de lercanidipina amorfo
US8097729B2 (en) 2005-09-16 2012-01-17 Glenmark Generics Ltd. Polymorphic form of lercanidipine hydrochloride and process for the preparation thereof
EP1963254A2 (en) 2005-09-21 2008-09-03 Torrent Pharmaceuticals Ltd Process for the preparation of lercanidipine and amorphous form of lercanidipine hydrochloride
SI2046745T1 (sl) 2006-08-04 2014-02-28 Recordati Ireland Limited Postopek za pripravo amorfnega lerkanidipin hidroklorida

Also Published As

Publication number Publication date
EP1856051A1 (en) 2007-11-21
DK1856051T3 (da) 2020-01-02
IL184349A0 (en) 2007-10-31
CN101124204A (zh) 2008-02-13
EA014383B1 (ru) 2010-10-29
NO344559B1 (no) 2020-02-03
JP2008531515A (ja) 2008-08-14
AU2006218026B9 (en) 2011-10-27
MY142129A (en) 2010-09-30
PL1856051T3 (pl) 2020-05-18
CA2598016A1 (en) 2006-08-31
US20060211742A1 (en) 2006-09-21
BRPI0608138A2 (pt) 2009-11-17
EA200701687A1 (ru) 2008-02-28
US7820701B2 (en) 2010-10-26
PE20061014A1 (es) 2006-10-03
UY29401A1 (es) 2006-06-30
AU2006218026B2 (en) 2009-04-02
ES2339213T3 (es) 2020-05-28
PT1856051T (pt) 2020-01-07
NO20074874L (no) 2007-11-26
ES2339213T1 (es) 2010-05-18
LT1856051T (lt) 2020-01-10
TW200640861A (en) 2006-12-01
WO2006089787A1 (en) 2006-08-31
RS59654B1 (sr) 2020-01-31
UA90130C2 (ru) 2010-04-12
KR20070105979A (ko) 2007-10-31
HUE046910T2 (hu) 2020-04-28
NZ556667A (en) 2009-10-30
MX2007010093A (es) 2007-10-12
AR052918A1 (es) 2007-04-11
SI1856051T1 (sl) 2020-02-28
HRP20192302T1 (hr) 2020-03-06
ME03659B (me) 2021-01-20
AU2006218026A1 (en) 2006-08-31
ZA200708127B (en) 2008-11-26
EP1856051B1 (en) 2019-11-13

Similar Documents

Publication Publication Date Title
CY1122429T1 (el) Αμορφη υδροχλωρικη λερκανιδιπινη
FIC20210022I1 (fi) tukatinibi, valinnaisesti farmaseuttisesti hyväksyttävän suolan tai solvaatin muodossa
NO20092611L (no) Krystallinsk faststoff Rasagilin base
CY1109888T1 (el) Προφαρμακα των ενωσεων 2,4-πυριμιδινδιαμινης και οι χρησεις αυτων
CY1117228T1 (el) Διεργασια για την παρασκευη συνθεσεων υδροχλωρικης οξυκωδονης που εχουν λιγοτερο απο 25 ppm 14-υδροξυκωδεϊνονη
CY1109010T1 (el) γ-ΚΡΥΣΤΑΛΛΙΚΗ ΜΟΡΦΗ ΤΗΣ ΥΔΡΟΧΛΩΡΙΚΗΣ ΙΒΑΒΡΑΔΙΝΗΣ, ΜΕΘΟΔΟΣ ΠΑΡΑΣΚΕΥΗΣ ΤΗΣ ΚΑΙ ΦΑΡΜΑΚΕΥΤΙΚΕΣ ΣΥΝΘΕΣΕΙΣ ΠΟΥ ΤΗΝ ΠΕΡΙΕΧΟΥΝ
CY1108843T1 (el) 3,11β cis διϋδροτετραβεναζινη για την θεραπεια της σχιζοφρενιας και αλλων ψυχωσεων
CY1106467T1 (el) Ελεγχομενη συνθεση ζιπρασιδονης
MX2008000141A (es) Moduladores de lxr basados en imidazol.
LTC1608344I2 (lt) Per burną vartojamos kladribino kompozicijos
TW200722100A (en) A therapeutic agent for a β related disorders
CY1106366T1 (el) Ενωση λακταμης για την αναστολη της απελευθερωσης ή της συνθεσης βητα-αμυλοειδους πεπτιδιου
CY1108547T1 (el) Αναλογα σωματοστατινης
RS50660B (sr) Dihidrotetrabenazini i farmaceutske kompozicije koje ih sadrže
MY143250A (en) Novel 1-aza bicycloalkyl derivatives for the treatment of psychotic and neurodegenerative disorders
CY1106682T1 (el) Ενωση λακταμης
AP1766A (en) Novel crystalline polymorphic forms of lercanidipine hydrochloride and process for their preparation.
NO20063293L (no) Farmasoytiske forbindelser
EP1845780A4 (en) USES OF METHYLPHENIDATE DERIVATIVES
EA200600590A1 (ru) Фармацевтические композиции модафинила с модифицированным высвобождением
ATE411310T1 (de) Reinigungsverfahren von moxonidine
CY1105699T1 (el) Νεες φαρμακευτικες ενωσεις με αλφα2υποδοχεα δραστηριοτητας
DK1919867T3 (da) Lisofyllinanaloger og farmaceutiske anvendelser heraf
NO20074439L (no) Benzoksazokiner og deres terapeutiske anvendelse
ATE328595T1 (de) Carvedilolpolymorph